http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 09 Jun 2026 06:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jun+03/26619556.html si-local-file:///var/storage/secattach/20260609/26619556.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jun+03/26619556.html Tue, 09 Jun 2026 06:01:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jun+03/26619556.html si-local-file:///var/storage/secattach/20260609/26619556.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jun+03/26619556.html Tue, 09 Jun 2026 06:01:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jun+04/26605930.html si-local-file:///var/storage/secattach/20260604/26605930.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jun+04/26605930.html Thu, 04 Jun 2026 16:16:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jun+04/26605930.html si-local-file:///var/storage/secattach/20260604/26605930.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++AN2+Therapeutics%2C+Inc.++++For%3A+Jun+04/26605930.html Thu, 04 Jun 2026 16:16:00 -0400 ANTX O.53806153 http://www.streetinsider.com/FDA/AN2+Therapeutics+reports+positive+data+for+Chagas+disease+drug/26602335.html <p>AN2 Therapeutics Inc. (NASDAQ: ANTX) reported results from two studies evaluating its oral drug AN2-502998 for chronic Chagas disease treatment.</p> <p>In a nonhuman primate study, 28 days of AN2-502998 treatment eliminated parasites in 100% of animals naturally infected with Trypanosoma cruzi at target exposures planned for humans. The elimination remained durable through four months following treatment completion.</p> <p>A Phase 1 first-in-human study showed the drug was generally well tolerated with no dose-limiting toxicities. Human plasma exposures at or above the efficacy thresholds observed in the primate study were achieved.</p> <p>The company plans to initiate a Phase 2 proof-of-concept study later this year. AN2-502998 http://www.streetinsider.com/FDA/AN2+Therapeutics+reports+positive+data+for+Chagas+disease+drug/26602335.html Thu, 04 Jun 2026 07:01:02 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/FDA/AN2+Therapeutics+reports+positive+data+for+Chagas+disease+drug/26602335.html <p>AN2 Therapeutics Inc. (NASDAQ: ANTX) reported results from two studies evaluating its oral drug AN2-502998 for chronic Chagas disease treatment.</p> <p>In a nonhuman primate study, 28 days of AN2-502998 treatment eliminated parasites in 100% of animals naturally infected with Trypanosoma cruzi at target exposures planned for humans. The elimination remained durable through four months following treatment completion.</p> <p>A Phase 1 first-in-human study showed the drug was generally well tolerated with no dose-limiting toxicities. Human plasma exposures at or above the efficacy thresholds observed in the primate study were achieved.</p> <p>The company plans to initiate a Phase 2 proof-of-concept study later this year. AN2-502998 http://www.streetinsider.com/FDA/AN2+Therapeutics+reports+positive+data+for+Chagas+disease+drug/26602335.html Thu, 04 Jun 2026 07:01:02 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/FDA/AN2+Therapeutics+reports+positive+data+for+Chagas+disease+drug/26602335.html <p>AN2 Therapeutics Inc. (NASDAQ: ANTX) reported results from two studies evaluating its oral drug AN2-502998 for chronic Chagas disease treatment.</p> <p>In a nonhuman primate study, 28 days of AN2-502998 treatment eliminated parasites in 100% of animals naturally infected with Trypanosoma cruzi at target exposures planned for humans. The elimination remained durable through four months following treatment completion.</p> <p>A Phase 1 first-in-human study showed the drug was generally well tolerated with no dose-limiting toxicities. Human plasma exposures at or above the efficacy thresholds observed in the primate study were achieved.</p> <p>The company plans to initiate a Phase 2 proof-of-concept study later this year. AN2-502998 http://www.streetinsider.com/FDA/AN2+Therapeutics+reports+positive+data+for+Chagas+disease+drug/26602335.html Thu, 04 Jun 2026 07:01:02 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/FDA/AN2+Therapeutics+reports+positive+data+for+Chagas+disease+drug/26602335.html <p>AN2 Therapeutics Inc. (NASDAQ: ANTX) reported results from two studies evaluating its oral drug AN2-502998 for chronic Chagas disease treatment.</p> <p>In a nonhuman primate study, 28 days of AN2-502998 treatment eliminated parasites in 100% of animals naturally infected with Trypanosoma cruzi at target exposures planned for humans. The elimination remained durable through four months following treatment completion.</p> <p>A Phase 1 first-in-human study showed the drug was generally well tolerated with no dose-limiting toxicities. Human plasma exposures at or above the efficacy thresholds observed in the primate study were achieved.</p> <p>The company plans to initiate a Phase 2 proof-of-concept study later this year. AN2-502998 http://www.streetinsider.com/FDA/AN2+Therapeutics+reports+positive+data+for+Chagas+disease+drug/26602335.html Thu, 04 Jun 2026 07:01:02 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html <p class="bwalignc"> <i>Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans</i> </p><p class="bwalignc"> <i>Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities</i> </p><p class="bwalignc"> <i>Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html Thu, 04 Jun 2026 07:00:00 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html <p class="bwalignc"> <i>Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans</i> </p><p class="bwalignc"> <i>Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities</i> </p><p class="bwalignc"> <i>Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html Thu, 04 Jun 2026 07:00:00 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html <p class="bwalignc"> <i>Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans</i> </p><p class="bwalignc"> <i>Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities</i> </p><p class="bwalignc"> <i>Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html Thu, 04 Jun 2026 07:00:00 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html <p class="bwalignc"> <i>Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans</i> </p><p class="bwalignc"> <i>Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities</i> </p><p class="bwalignc"> <i>Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html Thu, 04 Jun 2026 07:00:00 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html <p class="bwalignc"> <i>Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans</i> </p><p class="bwalignc"> <i>Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities</i> </p><p class="bwalignc"> <i>Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html Thu, 04 Jun 2026 07:00:00 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html <p class="bwalignc"> <i>Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans</i> </p><p class="bwalignc"> <i>Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities</i> </p><p class="bwalignc"> <i>Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html Thu, 04 Jun 2026 07:00:00 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html <p class="bwalignc"> <i>Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans</i> </p><p class="bwalignc"> <i>Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities</i> </p><p class="bwalignc"> <i>Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html Thu, 04 Jun 2026 07:00:00 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html <p class="bwalignc"> <i>Parasite elimination achieved with 28-day treatment in 100% of nonhuman primates (NHPs) naturally infected with Trypanosoma cruzi (T. cruzi) at target exposures planned in humans</i> </p><p class="bwalignc"> <i>Phase 1 First-In-Human (FIH) study showed favorable safety and tolerability profile; no dose-limiting toxicities</i> </p><p class="bwalignc"> <i>Significant U.S. commercial opportunity, including Priority Review Voucher eligibility upon approval</i> </p> <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced positive results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease (American trypanosomiasis) http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+Reports+Positive+Enabling+Data+Supporting+Advancement+of+Oral+AN2-502998+to+Phase+2+Study+for+Chronic+Chagas+Disease/26602284.html Thu, 04 Jun 2026 07:00:00 -0400 A.12989245 ANTX O.40287998 O.53806153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+May+29++Filed+by%3A+Williams+Sarah+Joanne/26592279.html si-local-file:///var/storage/secattach/20260602/26592279.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+May+29++Filed+by%3A+Williams+Sarah+Joanne/26592279.html Tue, 02 Jun 2026 16:32:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+May+29++Filed+by%3A+Williams+Sarah+Joanne/26592279.html si-local-file:///var/storage/secattach/20260602/26592279.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AN2+Therapeutics%2C+Inc.++++For%3A+May+29++Filed+by%3A+Williams+Sarah+Joanne/26592279.html Tue, 02 Jun 2026 16:32:00 -0400 ANTX O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+to+Present+at+2026+Jefferies+Global+Healthcare+Conference/26531259.html <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 12:50 PM ET, and members of management will be available for 1x1 meetings. </p><p> A webcast can be accessed on the Investors section of the AN2 Therapeutics website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.an2therapeutics.com&amp;esheet=54539545&amp;newsitemid=20260521162598&amp;lan=en-US&amp;anchor=www.an2therapeutics.com&amp;index=1&amp;md5=47dda304770a5cfec666143a71dd897a" shape="rect">www.an2therapeutics.com</a>. An archived replay will be available for at least 30 days following the presentation. </p><p> <b>About AN2 Therapeutics, Inc.</b> </p><p> AN2 Therapeutics, http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+to+Present+at+2026+Jefferies+Global+Healthcare+Conference/26531259.html Thu, 21 May 2026 07:00:00 -0400 ANTX O.53806153 http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+to+Present+at+2026+Jefferies+Global+Healthcare+Conference/26531259.html <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 12:50 PM ET, and members of management will be available for 1x1 meetings. </p><p> A webcast can be accessed on the Investors section of the AN2 Therapeutics website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.an2therapeutics.com&amp;esheet=54539545&amp;newsitemid=20260521162598&amp;lan=en-US&amp;anchor=www.an2therapeutics.com&amp;index=1&amp;md5=47dda304770a5cfec666143a71dd897a" shape="rect">www.an2therapeutics.com</a>. An archived replay will be available for at least 30 days following the presentation. </p><p> <b>About AN2 Therapeutics, Inc.</b> </p><p> AN2 Therapeutics, http://www.streetinsider.com/Press+Releases/AN2+Therapeutics+to+Present+at+2026+Jefferies+Global+Healthcare+Conference/26531259.html Thu, 21 May 2026 07:00:00 -0400 ANTX O.53806153 http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+to+Present+at+2026+Jefferies+Global+Healthcare+Conference/26531259.html <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 12:50 PM ET, and members of management will be available for 1x1 meetings. </p><p> A webcast can be accessed on the Investors section of the AN2 Therapeutics website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.an2therapeutics.com&amp;esheet=54539545&amp;newsitemid=20260521162598&amp;lan=en-US&amp;anchor=www.an2therapeutics.com&amp;index=1&amp;md5=47dda304770a5cfec666143a71dd897a" shape="rect">www.an2therapeutics.com</a>. An archived replay will be available for at least 30 days following the presentation. </p><p> <b>About AN2 Therapeutics, Inc.</b> </p><p> AN2 Therapeutics, http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+to+Present+at+2026+Jefferies+Global+Healthcare+Conference/26531259.html Thu, 21 May 2026 07:00:00 -0400 ANTX O.53806153 http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+to+Present+at+2026+Jefferies+Global+Healthcare+Conference/26531259.html <p> MENLO PARK, Calif.--(BUSINESS WIRE)-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 12:50 PM ET, and members of management will be available for 1x1 meetings. </p><p> A webcast can be accessed on the Investors section of the AN2 Therapeutics website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.an2therapeutics.com&amp;esheet=54539545&amp;newsitemid=20260521162598&amp;lan=en-US&amp;anchor=www.an2therapeutics.com&amp;index=1&amp;md5=47dda304770a5cfec666143a71dd897a" shape="rect">www.an2therapeutics.com</a>. An archived replay will be available for at least 30 days following the presentation. </p><p> <b>About AN2 Therapeutics, Inc.</b> </p><p> AN2 Therapeutics, http://www.streetinsider.com/Business+Wire/AN2+Therapeutics+to+Present+at+2026+Jefferies+Global+Healthcare+Conference/26531259.html Thu, 21 May 2026 07:00:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++AN2+Therapeutics%2C+Inc.+++++++++++++++++Filed+by%3A+Almitas+Capital+LLC/26508566.html si-local-file:///var/storage/secattach/20260515/26508566.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++AN2+Therapeutics%2C+Inc.+++++++++++++++++Filed+by%3A+Almitas+Capital+LLC/26508566.html Fri, 15 May 2026 21:59:00 -0400 ANTX O.53806153 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++AN2+Therapeutics%2C+Inc.+++++++++++++++++Filed+by%3A+Almitas+Capital+LLC/26508566.html si-local-file:///var/storage/secattach/20260515/26508566.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++AN2+Therapeutics%2C+Inc.+++++++++++++++++Filed+by%3A+Almitas+Capital+LLC/26508566.html Fri, 15 May 2026 21:59:00 -0400 ANTX O.53806153 http://www.streetinsider.com/Upgrades/Leerink+Partners+Upgrades+AN2+Therapeutics+%28ANTX%29+to+Outperform/26489185.html <p>Leerink Partners analyst Joseph Schwartz upgraded AN2 Therapeutics (NASDAQ: ANTX) from Market Perform to Outperform with a price target of $9.00.</p><p>For an analyst ratings summary and ratings history on AN2 Therapeutics <a href="http://www.streetinsider.com/rating_history.php?q=ANTX">click here</a>. For more ratings news on AN2 Therapeutics <a href="http://www.streetinsider.com/stock_lookup_news.php?q=ANTX&amp;type=analyst">click here</a>.</p><p>Shares of AN2 Therapeutics closed at $4.31 yesterday.</p> http://www.streetinsider.com/Upgrades/Leerink+Partners+Upgrades+AN2+Therapeutics+%28ANTX%29+to+Outperform/26489185.html Thu, 14 May 2026 06:08:27 -0400 ANTX